Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD228A in advanced solid tumors
NCT04042480Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Sep 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD228A in cutaneous melanoma (CM), pleural mesothelioma, breast cancer and 3 more, sponsored by Seagen Inc. Primary endpoints: Number of participants with adverse events at 3.5 years, Number of participants with laboratory abnormalities at 3.5 years and 1 more. Started Sep 2019; status: terminated.
02
Drugs
SGN-CD228A
03
Conditions
cutaneous melanoma (CM)pleural mesotheliomabreast cancernon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04042480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042480.